ROHIT MEHRA
@drmehrarohit
Urologic Pathologist , MLabs GU Service Line Director, Director Michigan Legacy Tissue Program, University of Michigan
Great case of TFE3-rearranged RCC with beautiful biphasic morphology- also shows that biphasic pattern is not unique to TFEB RCC #kidneycancer #Genomics #gupath @UMichPath #pathology #pathresidents #MedTwitter
Wow! This is truly #spatial - thank you for #AdvancingYourRNAscope with us and congratulations on this exciting publication.
Issue 13 is complete! On the cover: HSPCs in a 5dpf zebrafish early larva labelled with a myb RNAscope probe (magenta spots, bottom). Endothelial cells (green) are delineated in yellow (dorsal aorta), blue (vein) and white (supra-intestinal artery). See journals.biologists.com/dev/issue/152/…
Please join us in welcoming @DrRanaMcKay as our new Section Editor for Genitourinary Disease! Dr. McKay is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include precision medicine and biomarker development. @OncoAlert
Retroperitoneal nodule. Can you nail this one? 🔨🔎 Poll below 🗳️👇 #PathPuzzle 🕵️♂️ @UMichPath #Pathology #PathX #PathTwitter
thepathologist.com/issues/2025/ar… @pathologistmag #hemepath #pathology @UMichPath
Just published! @UMichPath faculty Drs. @RobHumbleMD , @rahulmannan and @drmehrarohit share the latest on diagnosing renal neoplasia in @KidneyCancerJ. This resource is essential for physicians aiming to enhance the diagnosis and treatment of Renal Cell Carcinomas and is a…
Treatment options for de novo metastatic hormone-sensitive #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter in a case-based discussion Dr. Agarwal emphasizes the importance of treatment intensification beyond ADT monotherapy, which remains…
👀 @UMichPath @ArulChinnaiyan 🥳
🔬 From gene fusions to AI to climate-driven disease—#CAP25 is where pathology meets the future. 🧠 Explore our cutting-edge courses and register now: brnw.ch/21wU3qe
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇
Genetic evaluation and screening for early detection of kidney cancer - a growing concept, making its way to clinic more frequently @OncoAlert
KIM1 is the most promising biomarker in RCC but how do we incorporate it into clinical practice? #KCRS25 @VincentWenxinXu We need to agree on what is high + randomised trials needed. It feels a distance away. Low levels may spare some adjuvant pembro but prospect testing needed.
Insightful discussions, cutting edge research, great speakers, multidisciplinary approach & an amazing audience- perfect #kidneycancer meeting @kidneycan #KCRS2025 #genomics #pathology #cancer
Need ethics on demand? 🍱 Why not Pathology Ethics. com? Created by Drs. Mirza & Tannenbaum + funded by @CAPFndn, this free, interactive platform helps pathology trainees navigate real-world dilemmas. Learn more here: brnw.ch/21wUdSn @Pathologists @KMirza
⭐️Kicking off #KCRS25 with an impactful presentation by @montypal on industry support for rare RCC trials👉 Phase 3 trials can be done in non-clear cell RCC and should define standards #kidneycancer @kidneycan @OncoAlert @urotoday
#KCRS25 Our second pre-meeting session explored how to design and run better clinical trials for rare kidney cancer subtypes: Lessons from Other Cancers with @VivekSubbiah Statistical Design Strategies with Wanling Xie Regulatory Pathways & Endpoints with @chana_weinstock…
🌟 @KimrynRathmell shares her story and inspires action to fight brain drain 🧠💨: empower early careers 🚀, mentor to create opportunity 🤝, and ensure institutions 🏛️ bring young voices to the table while valuing mentors fully 🌱✨ @kidneycan #kcrs25
“Invest in PEOPLE.” Powerful reminder from @KimrynRathmell at #KCRS25 Because curing kidney cancer starts with empowering the next generation. @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal @NazliDizman @yekeduz_emre @AlbigesL @MikeSerzanMD…
We’re honored to have @KimrynRathmell @OSUCCC_James as the keynote speaker for #KCRS25. Her talk, “Leading the Way in Fostering Early Careers with a Focus on Kidney Cancer,” highlighted the power of mentorship, investment in new talent, and a clear vision for the future of…
Pathologist representation at this year’s #KCRS25, one of my most important and favorite meetings each year. 🔬🩺🩻 #gupathology #workingtogethertofightRCC @PayalKapur5 @Unclassified1 @drmehrarohit @kidneycan @OncoAlert @urotoday
When you hear the words “kidney mass” “tumor” “lesion” or “growth” after a routine scan, it’s easy to feel alarmed. But not all kidney lesions are cancerous, especially if they are small. kidneycancer.org/small-kidney-t… #kidneycancer #smallrenalmass #srm
Tomorrow at 10am, don’t miss the Keynote at #KCRS25 @kidneycan Leading the Way in Fostering Early Careers - with a focus on kidney cancer, featuring the incredible @KimrynRathmell Inspiration guaranteed! 🔬